Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Jun;1(3):219-24.
doi: 10.1007/s11906-999-0024-7.

Relevance of heart rate as a risk factor in hypertension

Affiliations
Review

Relevance of heart rate as a risk factor in hypertension

P Palatini et al. Curr Hypertens Rep. 1999 Jun.

Abstract

Numerous studies have shown that resting heart rate is closely correlated with blood pressure and that it is prospectively related to the development of hypertension. Moreover, there is mounting evidence to indicate that a high heart rate is associated with increased cardiovascular morbidity and mortality. In this respect, heart rate can be considered both as a marker of risk and as an independent factor in the induction of risk. Sympathetic overactivity seems to be responsible for the increase in blood pressure and hematocrit, and for the metabolic abnormalities often observed in subjects with tachycardia. Experimental studies in monkeys have shown that heart rate can also exert a direct atherogenic action on the arteries through increased wall stress. Furthermore, tachycardia can favor the occurrence of ventricular arrhythmias and sudden death. Reduction of heart rate appears to be a reasonable additional goal of antihypertensive therapy, especially in subjects with increased sympathetic tone. Nondihydropyridine calcium antagonists and drugs with agonistic properties at the I1-imidazoline receptors of the rostral ventrolateral medulla may be drugs of choice for this purpose, but whether they offer a significant morbidity-mortality advantage must be proven in prospective trials.

PubMed Disclaimer

References

    1. Am Heart J. 1991 Jan;121(1 Pt 1):172-7 - PubMed
    1. J Hum Hypertens. 1997 Aug;11 Suppl 1:S19-27 - PubMed
    1. Hypertension. 1982 May-Jun;4(3):406-14 - PubMed
    1. J Cardiovasc Pharmacol. 1987;10 Suppl 2:S100-2; discussion S103 - PubMed
    1. Lab Invest. 1981 Jul;45(1):14-27 - PubMed

LinkOut - more resources